These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6527751)

  • 1. Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder.
    Winter M; Lehmann E; Scholz OB
    Neuropsychobiology; 1984; 12(2-3):115-21. PubMed ID: 6527751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential improvements from haloperidol in two types of schizophrenics.
    Lehmann E; Lienert GA
    Psychopharmacology (Berl); 1984; 84(1):96-7. PubMed ID: 6436897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.
    Donlon PT; Hopkin JT; Tupin JP; Wicks JJ; Wahba M; Meadow A
    Arch Gen Psychiatry; 1980 Jun; 37(6):691-5. PubMed ID: 7387340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of neuroleptic therapy in the self assessment of schizophrenic patients].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1987 Aug; 39(8):487-91. PubMed ID: 3685210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
    Schlör KH; Moises HW; Haas S; Rieger H
    Pharmacopsychiatry; 1985 Sep; 18(5):293-6. PubMed ID: 4048264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of haloperidol on thought disorder and IQ in schizophrenia.
    Gold JM; Hurt SW
    J Pers Assess; 1990; 54(1-2):390-400. PubMed ID: 2179521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
    Tuason VB
    J Clin Psychiatry; 1986 Mar; 47(3):126-9. PubMed ID: 3512535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients.
    Rinieris P; Hatzimanolis J; Markianos M; Stefanis C
    Neuropsychobiology; 1989; 22(3):146-9. PubMed ID: 2485861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of haloperidol.
    Man PL
    Dis Nerv Syst; 1973 Feb; 34(2):113-8. PubMed ID: 4267586
    [No Abstract]   [Full Text] [Related]  

  • 15. [Disagreement in standardized haloperidol treatment in comparison with "adequate individual dosage" of acutely schizophrenic patients].
    Klieser E; Lehmann E
    Fortschr Neurol Psychiatr; 1992 Mar; 60(3):126-9. PubMed ID: 1577361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Carbamazepine: an efficient adjuvant treatment in schizophrenia].
    Martín Muñoz JC; Moriñigo Domínguez AV; Mateo Martín I; Guajardo-Fajardo Ibarra I; Noval Lamos D
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1992; 20(1):11-6. PubMed ID: 1502960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial.
    Jungkunz G; Nedopil N; Rüther E
    Pharmacopsychiatry; 1984 May; 17(3):76-8. PubMed ID: 6739537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol.
    O'Brien CP; DiGiacomo JN; Webb W
    Dis Nerv Syst; 1974 Feb; 35(2):75-8. PubMed ID: 17894044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Haloperidol decanoate: results of a 6-month open trial in paranoid schizophrenia].
    Pérez C; Stier Rosner SE
    Acta Psiquiatr Psicol Am Lat; 1989; 35(3-4):111-5. PubMed ID: 2576990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.